News Headlines Article

Hepatitis C pill spurs debate over patents, prices overseas
San Francisco Chronicle

A cure for hepatitis C might seem like welcome news in India, where 12 million people suffer from the disease. But the country isn’t quite rolling out the red carpet for Sovaldi, the breakthrough drug by Gilead Sciences in Foster City.

Sovaldi is already controversial in the United States, where insurers, lawmakers and patients are outraged that a 12-week treatment costs $84,000. Health advocates also fear Indian patients, many of them poor and uninsured, cannot afford even a heavily discounted version of Sovaldi.